Cargando…

Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy

PURPOSE: Currently, trastuzumab plus chemotherapy is the standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (mGC) or esophagogastric junction cancer. However, it is not clear whether the prognosis of HER2-positive mGC treate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Gi-Young, Yang, Sung-Hyun, Kang, Hye-Jin, Lee, Hyo-Lak, Kim, Jin, Kim, Yun-Ju, Yu, Hang-Jong, Lee, Jong-Inn, Jin, Sung-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Surgical Oncology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942733/ https://www.ncbi.nlm.nih.gov/pubmed/36945715 http://dx.doi.org/10.14216/kjco.20011

Ejemplares similares

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Phenotypic Differences of Gastric Cancer according to the Helicobacter pylori Infection in Korean Patients
por: Park, Dong-Wook, et al.
Publicado: (2010)

Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
por: Choi, In Sil, et al.
Publicado: (2018)

A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
por: Choi, In Sil, et al.
Publicado: (2018)

Time-Dependent Effects of Prognostic Factors in Advanced Gastric Cancer Patients
por: Kwon, Jin-Ok, et al.
Publicado: (2015)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
por: Lee, Seul, et al.
Publicado: (2017)

Hepatic Resection for Hepatic Metastases from Gastric Adenocarcinoma
por: Baek, Hyoung-Un, et al.
Publicado: (2013)

Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection
por: Lee, Ji Hyun, et al.
Publicado: (2011)

Actual compliance to adjuvant chemotherapy in gastric cancer
por: Kim, Dong-Wook, et al.
Publicado: (2019)

FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment
por: Chae, Heejung, et al.
Publicado: (2018)

Differences in the performance of health officers at the workplace according to their qualifications
por: Kim, Yeong-Kwang, et al.
Publicado: (2018)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment
por: Yoon, Sung Hyun, et al.
Publicado: (2016)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy
por: Kim, Jae-Min, et al.
Publicado: (2021)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
por: Hwang, Jun-Eul, et al.
Publicado: (2011)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Schneider, Jean, et al.
Publicado: (2020)

Risk Stratification for Serosal Invasion Using Preoperative Predictors in Patients with Advanced Gastric Cancer
por: Park, Sung-Sil, et al.
Publicado: (2012)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Training Effect on the Inter-observer Agreement in Endoscopic Diagnosis and Grading of Atrophic Gastritis according to Level of Endoscopic Experience
por: Jin, Eun Hyo, et al.
Publicado: (2018)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
por: Zhang, Yanqiang, et al.
Publicado: (2022)

Test Execution Variation in Peritoneal Lavage Cytology Could Be Related to Poor Diagnostic Accuracy and Stage Migration in Patients with Gastric Cancer
por: Ki, Young-Jun, et al.
Publicado: (2013)

Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy
por: Yoo, Shin Hye, et al.
Publicado: (2017)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
por: Koh, Jiwon, et al.
Publicado: (2019)

Comparison of Prevalence and Ultrasonography Features of Thyroglossal Duct Cyst in Adults According to Radioactive Iodine Ablation
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
por: Hong, Yong Joo, et al.
Publicado: (2014)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2021)

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
por: Lee, Choong-kun, et al.
Publicado: (2022)

Prevalence and Features of Thyroglossal Duct Cyst on Ultrasonography, According to Radioactive Iodine Therapy: A Single-Center Study
por: Park, Ji Sun, et al.
Publicado: (2020)

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
por: Yoo, Shin Hye, et al.
Publicado: (2021)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hoep779gfn20ljjb5gf3p0f6jh